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following a 2-week, open-label, observation period during which subjects continued 
to receive olanzapine. The rate of ATP-I Il metabolic syndrome, and the long term 
risk for diabetes and CHD was estimated and compared between arms. Brazilian costs 
and health resource estimates were applied to each event. Established risk functions 
were used to estimate diabetes and CHD risk. RESULTS: Among all patients, the 
baseline rate of metabolic syndrome was 89%. At 16 weeks, 80.3% of olanzapine 
versus 60% of aripiprazole patients exhibited metabolic syndrome (RR: 0.75; 95%Cl: 
0.61–0.92, p  0.006). Diabetes risk increased by 1.3% (aripiprazole patients) and 
6.4% (olanzapine patients), risk difference  5.1 %. CHD risk decreased by 0.6% 
(aripiprazole patients) and increased by 0.3% (olanzapine patients), risk difference  
0.9%. Among 1000 patients, treatment with aripiprazole versus olanzapine would 
avert 203 metabolic syndrome events, 51 diabetes events, and 9 CHD events at a cost 
of R$1,520.63, R$1.856, and R$4,122.31, per event avoided respectively. The total 
cost difference was R$440,442. Risk differences were driven primarily by signiﬁcant 
weight and lipid changes between agents, favoring aripiprazole. CONCLUSIONS: 
Antipsychotic-related metabolic adverse events and the consequent risk of diabetes 
and CHD can add substantively to health care costs among patients with schizophre-
nia in Brazil. Health care providers should consider these risks in the selection of 
appropriate antipsychotic agents.
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OBJECTIVES: To assess the cost-effectiveness of treatment of schizophrenia with 
Risperidone long acting injectable (RLAI) in comparison with oral Quetiapine using 
an economic model. METHODS: A decision-tree model was built using a treatment 
algorithm simulating the Brazilian Public Health System and applying the rehospital-
ization rates extracted from a 2-year head-to-head study which compared RLAI and 
oral quetiapine. Cost data were extracted from an analysis of direct cost of hospitaliza-
tion in a Brazilian public mental health hospital. As usual in the Public Health System, 
patients considered in this model had previously used Oral Risperidone and were 
elegible to use other second-generation antipsychotics, as well as switch to others. 
RESULTS: In the head-to-head comparison, patients treated with RLAI had a rehos-
pitalization rate of 33.1%, while patients treated with Quetiapine had a rehospitaliza-
tion rate of 16.5% (p  0.0001). In a hypothetical cohort of 1000 patients followed 
for two years, the number of hospital days was 3.3 higher in the Quetiapine group, 
and the number of patients requiring hospitalization in the Quetiapine group was 1.8 
higher, which represent 139 patients without hospitalization in the RLAI group in the 
same period. Mean number of days at hospital was lower with RLAI (32 days) than 
with Quetiapine (64 days). RLAI was the treatment with lower direct cost, generating 
an annual saving of R$1040.00 per patient in the Public System. CONCLUSIONS: 
In comparison with Quetiapine, RLAI is cost saving, due to lower rehospitalization 
rates.
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OBJETIVOS: A Medicina Baseada em Evidências é importante por fornecer indica-
dores que avaliam a eﬁcácia de tratamento em perceptiva mais prática, como o número 
necessário tratar (NNT), que representa o número de pacientes que é necessário tratar 
para obter um desfecho favorável, comparado a taxa de sucesso do grupo controle. 
O NNT é útil na tomada de decisão, pois demonstra pelo impacto orçamentário não 
só o “custo de sucesso” (custo efetividade) mas tambem o “custo de desperdício”. Um 
NNT de 7.0 signiﬁca que é necessário tratar 7 pacientes para obteção de um desfecho 
favorável, signiﬁcando que 6 pacientes foram tratados sem sucesso. O Sistema de 
Saúde Público (SUS) do Brasil apresenta atualmente altos custos no tratamento da 
esquizofrenia. Paliperidona é um novo antipsicótico atípico oral de liberação pro-
longada e dose diária única.O objetivo é demonstrar por análise de custo efetividade 
baseada em NNT,o custo para obtenção de sucesso clínico, para antipsicóticos atípicos 
(paliperidona, olanzapina, quetiapina, ziprazidona, aripiprazol). MÉTODOS: Os 
valores de NNT utilizados para olanzapina, ziprasidona, quetiapina e aripiprazol 
foram obtidos de revisões sistemáticas da Cochrane. O NNT da paliperidona foi reti-
rado da bula. Para cálculo dos custos diários de tratamento foi utilizada a Dose Diária 
Deﬁnida (DDD) e preços retirados da revista indexada. RESULTADOS: Os valores 
de NNT encontrados foram: 7.0 olanzapina, 5.0 aripiprazol, 7.0 ziprasidona e 8.0 
quetiapina. Para paliperidona, o NNT obtido foi 3.87. Os custos para obter um 
sucesso clínico foram, R$3,851 (olanzapina), R$ 2,747 (aripiprazol), R$2,423 
(ziprasidona), R$6,115 (quetiapina) e R$2,003 (paliperidona). CONCLUSÕES: 
 Paliperidona demonstrou o melhor NNT e o menor “custo de sucesso clinico” com-
parada aos outros atípicos. Assim, a escolha do tratamento com a paliperidona torna-
se uma opção eﬁciente.
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OBJECTIVOS: Evaluar la costo-utilidad de los principales medicamentos antipsicóti-
cos en el contexto colombiano. METODOLOGÍAS: Con un modelo de árbol de 
decisión (horizonte temporal de un año, perspectiva de tercero pagador), se simulan 
ocho medicamentos antipsicóticos: haloperidol y siete atípicos (aripiprazol, clozapina, 
olanzapina, paliperidona, quetiapina, risperidona y ziprasidona). Se utilizaron datos 
de efectividad y adherencia del estudio CATIE, los valores de haloperidol, clozapina 
y paliperidona se obtuvieron de estudios clínicos y panel de expertos locales. Los 
eventos adversos se obtuvieron de estudios clínicos. Los costos directos sanitarios 
corresponden al valor de facturación de prestadores de servicios de salud locales y la 
calidad de vida en QALY se obtuvo del registro de utilidades de Tufts. Tasa de cambio 
US$1  Col$2391. RESULTADOS: El costo de atención en salud anual promedio fue: 
haloperidol US$1724, paliperidona US$2263, risperidona US$2546, clozapina 
US$2963, ziprasidona US$2998, quetiapina US$3500, olanzapina US$3645, y aripip-
razol US$3890. Comparado con haloperidol, la menor razón incremental de costo-
utilidad corresponde a paliperidona (US$25.8K / QALY). En los otros atípicos, ésta 
varía entre US$54K (risperidona) y US$238K (aripiprazol). Estos valores estarían 
magniﬁcados por las pequeñas diferencias en utilidades (entre 0.63 QALY para halo-
peridol y 0.65 QALY para olanzapina y paliperidona). Considerando lo anterior, cal-
culamos el beneﬁcio neto. Con una disponibilidad a pagar de US$25K por QALY, 
haloperidol y paliperidona generarían un beneﬁcio similar (US$14.1K) que es mayor 
al de cualquier otro atípico (entre US$12.7K con olanzapina y US$13.7K con risperi-
dona). CONCLUSIONES: Haloperidol sigue siendo el antipsicótico más costo- 
efectivo en el mercado. En este modelo, que minimiza diferencias en efectividad, el 
único antipsicótico costo-efectivo comparable con haloperidol es la paliperidona. Un 
trabajo posterior incluirá costos indirectos y un seguimiento mayor. Estos resultados 
sugieren que paliperidona sería el medicamento de elección al prescribir un antip-
sicótico atípico oral.
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OBJECTIVES: Depression is one of the most frequent mental health ailments. It has 
been estimated that by year 2020, it will be the worldwide second cause for the loss 
of healthy life years and the ﬁrst cause in developed countries. In Mexico, the preva-
lence of major depression is estimated from 7% to 12%. However there is not infor-
mation regarding health care resources use in Mexico for this pathology. This, study’s 
objective is to document the health care resource use for depression treatment in 
Mexico. METHODS: Twenty one mental health specialists from a public health 
institution were asked to answer a questionary. Additionally, modiﬁed Delphi method 
was applied with eight specialist to further analyze some of the topics. A database 
was created from the answers and a statistic analysis was performed. RESULTS: Sixty 
percent of the ambulatory patients of the psiquatric area turn to the specialist due to 
depression and from these 40% due to major depression. Eighteen percent of the 
depression patients require hospitalization and, in average, they stay in the hospital 
25 days. Approximately 39% of the patients with major depression become handi-
capped 3 periods of 14 days during the treatment. The average prescription time for 
the anti-depressive drugs is 11.3 months; however, the specialist reported that the 
prescription time could be from 4 to 27 months. CONCLUSIONS: This study provides 
base line information regarding the use of health care resources use in the treatment 
of depressed patients in Mexico. Further evaluations of the disease burden in the 
country should be performed.
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OBJECTIVOS: Identiﬁcar los factores asociados al incumplimiento de tratamientos 
con antidepresivos (AD) en Santiago, Chile. METODOLOGÍAS: Mediante un estudio 
transversal se entrevistó en hogares a una muestra representativa y probabilística de 
1000 personas q 15 años en Santiago, Chile. Los datos se analizaron a través de 
estadística descriptiva y regresiones logísticas con STATA 8.0. RESULTADOS: De los 
171(17.1%)sujetos que declararon haber consumido alguna vez en su vida AD, el 
52.4% declaró ser incumplidor para dosis, tiempo recomendado de uso y/o ambas 
(33.2% para dosis y 38.3% para tiempo de uso). Al estudiar el incumplimiento al 
tiempo recomendado de uso, se observaron diferencias signiﬁcativas en Grupo Socio-
económico (GSE) bajo que presentó 5.3 veces más riesgo de incumplimiento que GSE 
alto (OR  5.3; IC95% 1.51–18.40; p  0.009). La condición de mujer con GSE 
medio-alto y bajo presentó más riesgo de incumplimiento que mujer de GSE alto (OR 
 3.95; IC95% 1.29–12.15; p  0.016) y (OR  4.3; IC95% 1.11–16.52; p  0.035), 
respectivamente. Además, al estudiar el incumplimiento a la dosis prescrita se observó 
